
-
Taiwan exporters count the cost of Trump's 'ridiculous' tariffs
-
Injury-time goal gives Brazil first win over US women since 2014
-
Japan badminton ace Shida blasts 'stalker' Chinese fans
-
Ekitike has Frankfurt dreaming of Europa League repeat
-
Trump's new tariffs take effect, with 104% on Chinese goods
-
Shai scores 42, Doncic ejected as Thunder down Lakers
-
Nepal royalists seek return of king
-
Man Utd reliant on Europa League with season on life support
-
Kim Jong Un's sister says North Korea denuclearisation is a 'daydream'
-
Trump tariffs leave Italy's luxury furniture makers sitting uncomfortably
-
EU plan to end Russian fertiliser imports unsettles farmers
-
Equities resume selloff as Trump cranks up trade war
-
Inside Europe's last 'open-outcry' trading floor
-
Trumps presses on with 104% tariffs on China
-
AI tool aims to help conserve Japan's cherry trees
-
The Metals Company courts Trump for deep-sea mining contract
-
Indonesia president says ready to temporarily shelter Gazans
-
Musk brands Trump aide 'dumber than a sack of bricks' in tariff spat
-
Author of explosive Meta memoir to star at US Senate hearing
-
UK to host Europe's first Universal theme park
-
'It's beautiful': Arteta hails Rice free-kick magic as Arsenal stun Real
-
Argentine Congress backs inquiry into Milei crypto scandal
-
US will not let China disrupt Panama Canal: Pentagon chief
-
Judge orders White House to restore AP access
-
Shaken Real Madrid insist Arsenal comeback possible
-
Bayern 'fully believe' despite Inter setback, says Kompany
-
Inter 'showed what we were made of' against Bayern, says Martinez
-
US stocks fall again as global rally fizzles
-
Milan's England defender Walker has surgery on broken elbow
-
Judge orders White House to lift restrictions on AP access
-
Free-kick hero Rice revels in Arsenal's 'special' win over Real
-
'Totally new': Scheffler readies for Masters defense
-
Stuffy nose and steak knife join Scheffler's list of Masters tests
-
Late Frattesi strike gives Inter edge over Bayern in Champions League
-
Arsenal stun Real Madrid as Rice delivers free-kick masterclass
-
Spain thump Portugal in women's Nations League as Belgium upset England
-
Spain enjoy goal spree against Portugal in women's Nations League as Belgium upset England
-
Emery relishes Aston Villa's 'huge challenge' against PSG
-
Rahm on LIV-PGA solution: not happening soon
-
US, China clash as Trump set to unleash more tariffs
-
Cabrera returns to Masters with regrets in second chance at life
-
No.4 Morikawa ponders career Slam with Masters in his sights
-
French parliament restricts birthright citizenship in Mayotte
-
Meghan Markle reveals pregnancy-related medical complications
-
Spain enjoy goalfest against Portugal in women's Nations League as France edge Norway
-
Patrick Mullins hit with eight-day whip ban over Grand National ride
-
Patrick Mullins suspended for winning Grand National ride
-
Trump plants 'MAGAnolia' to replace 200-year-old tree
-
Pooran, Arya break free as Lucknow and Punjab win in IPL
-
NBA Nuggets fire coach Michael Malone

The scientist rewriting DNA, and the future of medicine
A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.
A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.
He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.
He will receive $3 million for his work on "base editing" and "prime editing," and plans to donate most of it to support his charitable foundation.
"The ability to change a DNA sequence of our choosing into a new sequence of our choosing is a fundamentally very powerful capability," the 51-year-old said, foreseeing uses not just in human medicine but areas like developing more nutritious or disease-resistant crops.
- Correcting the code -
DNA is made up of four chemical "letters" -- the nucleotide bases A, G, T and C. Mutations in this sequence cause thousands of human diseases, yet until recently, gene editing could only fix a limited number of them.
Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations.
It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct genes, while the process can introduce new errors.
"Being able to use genome editing to treat genetic diseases requires, in most cases, ways to correct a DNA misspelling, not simply to disrupt a gene," Liu said.
That insight led his lab to develop base editing, which uses the Cas9 protein -- disabled so it can no longer cut both DNA strands -- to find a target DNA sequence and another enzyme to convert one letter to another -- for example, C to T or G to A.
Reversing the change -- from T to C or A to G -- was tougher. Liu's team overcame the challenge by engineering entirely new enzymes.
These base editors can now correct about 30 percent of the mutations that cause genetic diseases. The technology is already in at least 14 clinical trials.
In one of them, Beam Therapeutics -- which Liu co-founded -- announced it had treated patients of AATD, a rare genetic disorder affecting the lungs and liver, with a single drug infusion.
While traditional gene therapies often disrupt faulty genes or work around them, base editing repairs the mutation itself.
"This was the first time that humans have corrected a mutation that causes a genetic disease in a patient," Liu said.
- Cystic fibrosis hope -
Base editing, quickly dubbed "CRISPR 2.0," can't fix every mutation.
About 70 percent of the roughly 100,000 known disease-causing mutations remain out of its reach, including those caused by missing or extra letters.
To expand the toolkit, Liu's lab introduced prime editing in 2019 -- a method capable of replacing entire sections of faulty DNA with corrected sequences.
If CRISPR is like scissors that cut DNA, and base editors are like using a pencil to correct individual letters, then prime editing is the equivalent of a word processor's "find and replace" function.
Creating this tool required a series of breakthroughs Liu's team describes as "small miracles." The result is, he said, "the most versatile way we know of to edit the human genome."
Among the targets Liu and his team have already pursued with prime editing: cystic fibrosis, a common genetic disease usually caused by three missing DNA letters that causes thick mucus buildup in the lungs and digestive system.
Liu's lab has made much of its work freely accessible, sharing DNA blueprints through a nonprofit library used by tens of thousands of labs worldwide.
"The science we create -- which is ultimately funded by society, through governments and donors -- ultimately goes back to benefit society."
This year's Breakthrough Prize awards come at a fraught moment for US science, as President Donald Trump's government strips funding for institutions like the National Institutes of Health (NIH).
"The NIH is a treasure, not just for this country but for the world," said Liu. "Trying to dismantle the heart of what supports science in this country is like burning your seed corn."
O.Gutierrez--AT